Search
Displaying 171–180 of 660 for “retinal diseases”
-
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Research NewsEditas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
Disease
X-linked retinoschisis (XLRS) is an inherited retinal disease causing vision loss due to splitting of the layers of the retina.
-
Need-to-Know Information about Clinical Trials
Research NewsA primer on what you can expect from clinical trials.
-
Research News
More good news about treatments and technological advances for restoring vision for people with retinal diseases.
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Research News
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Foundation News
The four-year study will inform clinical trial design for emerging USH3 therapies.
-
Eye on the Cure Podcast | Episode 63: Dr. Hema Ramkumar
Eye on the CureHema Ramkumar, MD, a retinal specialist, surgeon, and founder of the company Oculogenex, talks with host Ben Shaberman about her emerging therapy that targets mitchondria to slow the progression of intermediate dry age-related macular degeneration and potentially other retinal diseases. She also discusses her experiment that will put mice in space so researchers can gain a better understanding of retinal degeneration.
